 Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF said it has acquired KetaMD Inc, a US-based telemedicine company focused on addressing mental health challenges through access to technology-facilitated ketamine-based treatments. Today marks a notable step forward in bringing awareness, accessibility and scalability of the benefits of ketamine and psychedelics generally for those suffering from depression and other mood disorders, Braxia Scientific CEO Dr Roger McIntyre said in a statement. 